A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
Abstract Background Adrenal androgens play an important role in the development of castration-resistant prostate cancer therapeutics. The effect of gonadotropin-releasing hormone (GnRH) antagonists on adrenal androgens has not been studied sufficiently. We measured testicular and adrenal androgen le...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-08-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12894-017-0261-z |
| _version_ | 1819076147019776000 |
|---|---|
| author | Yoshiyuki Miyazawa Yoshitaka Sekine Takahiro Syuto Masashi Nomura Hidekazu Koike Hiroshi Matsui Yasuhiro Shibata Kazuto Ito Kazuhiro Suzuki |
| author_facet | Yoshiyuki Miyazawa Yoshitaka Sekine Takahiro Syuto Masashi Nomura Hidekazu Koike Hiroshi Matsui Yasuhiro Shibata Kazuto Ito Kazuhiro Suzuki |
| author_sort | Yoshiyuki Miyazawa |
| collection | DOAJ |
| description | Abstract Background Adrenal androgens play an important role in the development of castration-resistant prostate cancer therapeutics. The effect of gonadotropin-releasing hormone (GnRH) antagonists on adrenal androgens has not been studied sufficiently. We measured testicular and adrenal androgen levels in patients treated with a GnRH antagonist. Methods This study included 47 patients with histologically proven prostate cancer. All of the patients were treated with the GnRH antagonist degarelix. The mean patient age was 73.6 years. Pre-treatment blood samples were collected from all of the patients, and post-treatment samples were taken at 1, 3, 6, and 12 months after starting treatment. Testosterone (T), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), 17β-estradiol (E2), and androstenedione (A-dione) were measured by liquid chromatography-mass spectrometry. Dehydroepiandrosterone-sulfate (DHEA-S), luteinizing hormone, and follicle-stimulating hormone levels were measured by electro-chemiluminescence immunoassays. Results A significant reduction in T level (97.3% reduction) was observed in the patients 1 month after initiating treatment. In addition, levels of DHT, E2, DHEA-S, and A-dione decreased 1 month after initiating treatment (93.3, 84.9, 16.8, and 35.9% reduction, respectively). T, DHT, E2, DHEA-S, and A-dione levels remained significantly suppressed (97.1, 94.6, 85.3, 23.9, and 40.5% reduction, respectively) 12 months after initiating treatment. A significant decrease in DHEA level (15.4% reduction) was observed 12 months after initiating treatment. Conclusions Serum adrenal androgen levels decreased significantly in patients treated with a GnRH antagonist. Thus, long-term GnRH antagonist treatment may reduce serum adrenal androgen levels. |
| first_indexed | 2024-12-21T18:36:40Z |
| format | Article |
| id | doaj.art-5a75d88b7d5147bfbdeb004e9018a24f |
| institution | Directory Open Access Journal |
| issn | 1471-2490 |
| language | English |
| last_indexed | 2024-12-21T18:36:40Z |
| publishDate | 2017-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj.art-5a75d88b7d5147bfbdeb004e9018a24f2022-12-21T18:54:07ZengBMCBMC Urology1471-24902017-08-011711610.1186/s12894-017-0261-zA gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patientsYoshiyuki Miyazawa0Yoshitaka Sekine1Takahiro Syuto2Masashi Nomura3Hidekazu Koike4Hiroshi Matsui5Yasuhiro Shibata6Kazuto Ito7Kazuhiro Suzuki8Department of Urology, Gunma University Graduate School of MedicineDepartment of Urology, Gunma University Graduate School of MedicineDepartment of Urology, Gunma University Graduate School of MedicineDepartment of Urology, Gunma University Graduate School of MedicineDepartment of Urology, Gunma University Graduate School of MedicineDepartment of Urology, Gunma University Graduate School of MedicineDepartment of Urology, Gunma University Graduate School of MedicineDepartment of Urology, Gunma University Graduate School of MedicineDepartment of Urology, Gunma University Graduate School of MedicineAbstract Background Adrenal androgens play an important role in the development of castration-resistant prostate cancer therapeutics. The effect of gonadotropin-releasing hormone (GnRH) antagonists on adrenal androgens has not been studied sufficiently. We measured testicular and adrenal androgen levels in patients treated with a GnRH antagonist. Methods This study included 47 patients with histologically proven prostate cancer. All of the patients were treated with the GnRH antagonist degarelix. The mean patient age was 73.6 years. Pre-treatment blood samples were collected from all of the patients, and post-treatment samples were taken at 1, 3, 6, and 12 months after starting treatment. Testosterone (T), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), 17β-estradiol (E2), and androstenedione (A-dione) were measured by liquid chromatography-mass spectrometry. Dehydroepiandrosterone-sulfate (DHEA-S), luteinizing hormone, and follicle-stimulating hormone levels were measured by electro-chemiluminescence immunoassays. Results A significant reduction in T level (97.3% reduction) was observed in the patients 1 month after initiating treatment. In addition, levels of DHT, E2, DHEA-S, and A-dione decreased 1 month after initiating treatment (93.3, 84.9, 16.8, and 35.9% reduction, respectively). T, DHT, E2, DHEA-S, and A-dione levels remained significantly suppressed (97.1, 94.6, 85.3, 23.9, and 40.5% reduction, respectively) 12 months after initiating treatment. A significant decrease in DHEA level (15.4% reduction) was observed 12 months after initiating treatment. Conclusions Serum adrenal androgen levels decreased significantly in patients treated with a GnRH antagonist. Thus, long-term GnRH antagonist treatment may reduce serum adrenal androgen levels.http://link.springer.com/article/10.1186/s12894-017-0261-zProstate cancerGnRH antagonistAdrenal androgen |
| spellingShingle | Yoshiyuki Miyazawa Yoshitaka Sekine Takahiro Syuto Masashi Nomura Hidekazu Koike Hiroshi Matsui Yasuhiro Shibata Kazuto Ito Kazuhiro Suzuki A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients BMC Urology Prostate cancer GnRH antagonist Adrenal androgen |
| title | A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients |
| title_full | A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients |
| title_fullStr | A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients |
| title_full_unstemmed | A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients |
| title_short | A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients |
| title_sort | gonadotropin releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients |
| topic | Prostate cancer GnRH antagonist Adrenal androgen |
| url | http://link.springer.com/article/10.1186/s12894-017-0261-z |
| work_keys_str_mv | AT yoshiyukimiyazawa agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT yoshitakasekine agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT takahirosyuto agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT masashinomura agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT hidekazukoike agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT hiroshimatsui agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT yasuhiroshibata agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT kazutoito agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT kazuhirosuzuki agonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT yoshiyukimiyazawa gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT yoshitakasekine gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT takahirosyuto gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT masashinomura gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT hidekazukoike gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT hiroshimatsui gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT yasuhiroshibata gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT kazutoito gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients AT kazuhirosuzuki gonadotropinreleasinghormoneantagonistreducesserumadrenalandrogenlevelsinprostatecancerpatients |